New Real-World Case Series Examines Re-Induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial…
-
-
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (nadofaragene firadenovec-vncg)
Accelerated water-bath thawing, completed in about 25 minutes, may help streamline…
-
Ferring Announces Update to NCCN Guidelines Expanding Category 2A Recommendation for Nadofaragene Firadenovec-vncg (ADSTILADRIN®) in Patients with BCG-Unresponsive NMIBC
Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with…
-
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination…
-
SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant
Research grant empowers future leaders in clinical research to advance breakthroughs in the prevention, detection, diagnosis and treatment of NMIBC…
-
Ferring Applauds New Jersey and Michigan for Proclamations Recognizing November as C. Difficile Infection Awareness Month
Parsippany, NJ – November 12, 2025 – Ferring Pharmaceuticals thanks New Jersey and Michigan for recognizing November as Clostridioides difficile…
-
Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including…
-
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025
Analyses from the two Phase 3 RITA trials evaluate both the suitability of age-based dosing as well as the tolerability…
-
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2025
Oral presentation highlights microbiome restoration through six months with REBYOTA from Phase 3b CDI-SCOPE trial New data from CDI-SCOPE evaluating…
-
Ferring Presents New Real-World REBYOTA® (fecal microbiota, live – jslm) Data Underscoring Effectiveness and Significant Improvements in Patient Quality of Life
Results from two real-world studies, presented at IDWeek 2025, include initial registry findings and highlight consistent efficacy and safety of…